Quick Summary
- FDA approved VENCLEXTA (venetoclax) and acalabrutinib combination for previously untreated chronic lymphocytic leukemia (CLL) patients.
- First and only all-oral, fixed-duration combination regimen available for first-line CLL treatment.
- Approval based on Phase 3 AMPLIFY trial data.
AbbVie announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia (CLL). This milestone approval, supported by the Phase 3 AMPLIFY trial, establishes a significant advancement in how frontline CLL patients can be treated.
A New Standard in CLL Treatment
The FDA approval marks a watershed moment for CLL therapy. VENCLEXTA and acalabrutinib together represent the first and only all-oral, fixed-duration combination regimen available for patients with untreated CLL. This approval expands treatment options while maintaining the flexibility that healthcare providers and their patients need when making complex treatment decisions.
Unlike many traditional approaches that require prolonged, continuous therapy, the VENCLEXTA and acalabrutinib combination offers patients the potential for time off treatment a meaningful shift in long-term disease management that addresses one of the primary concerns patients face during CLL treatment.
This FDA approval marks a significant milestone for AbbVie and, more importantly, for people living with CLL.
As the first and only all-oral, fixed-duration combination regimen for previously untreated patients, the VENCLEXTA plus acalabrutinib approval expands choice and flexibility for patients and providers navigating complex treatment decisions in CLL.
Svetlana Kobina
Understanding Chronic Lymphocytic Leukemia
CLL represents one of the most prevalent forms of leukemia in adults. This blood cancer originates in the bone marrow and develops from cells that mature into lymphocytes, specialized white blood cells critical for immune function. While advances over recent years have significantly improved outcomes for CLL patients, the disease still presents substantial challenges for those who must manage it.
Patients with CLL often contend with extended treatment timelines and ongoing disease management complications that can impact quality of life. The introduction of oral combination therapies that offer fixed-duration treatment has the potential to address these concerns by allowing patients periods without active medication after completing their prescribed course.
What the AMPLIFY Trial Demonstrated
The FDA approval rests on compelling evidence from the Phase 3 AMPLIFY trial, an AstraZeneca-sponsored global multicenter study. This randomized trial evaluated VENCLEXTA plus acalabrutinib (administered both alone and in combination with obinutuzumab) against standard chemoimmunotherapy in patients with previously untreated CLL who did not have del(17p) or TP53 mutations.
The AMPLIFY trial’s results were decisive. The fixed-duration combination of VENCLEXTA and acalabrutinib demonstrated superior efficacy compared to chemoimmunotherapy regimens:
- Disease Progression Risk: The combination regimen reduced the risk of disease progression or death by 35 percent versus chemoimmunotherapy (HR 0.65; 95% CI: 0.49-0.87; p=0.0038)
- Progression-Free Survival: Median progression-free survival (PFS) was not reached for patients receiving VENCLEXTA and acalabrutinib, compared to 47.6 months for those on chemoimmunotherapy
- Treatment Duration: Patients received the fixed-duration combination for 14 cycles (every 28 days), while chemoimmunotherapy was administered for six cycles
Read More: Lilly’s Jaypirca Outperforms Imbruvica in Landmark Phase 3 Trial for CLL/SLL
Safety Profile: What Patients Should Know
The safety profile of the VENCLEXTA and acalabrutinib combination remains consistent with what has been observed for each drug administered individually. The AMPLIFY study identified no new safety signals, and researchers noted that the combination’s tolerability aligns with expectations based on single-agent experience.
Most Common Adverse Reactions (≥20%):
- Neutropenia (low white blood cell counts)
- Headache
- Diarrhea
- Musculoskeletal pain
- COVID-19
Most Serious Adverse Reactions (≥2%):
- COVID-19, including COVID-19 pneumonia (9%)
- Second primary malignancies (2.7%)
- Neutropenia (2.1%)
How VENCLEXTA Works: BCL-2 Inhibition?
VENCLEXTA (venetoclax) represents a first-in-class therapeutic breakthrough. The medication selectively binds to and inhibits BCL-2 (B-cell lymphoma-2), a protein that plays a crucial role in cancer cell survival.
In blood cancers like CLL, cancer cells exploit BCL-2’s natural function, preventing cells from undergoing apoptosis, the programmed cell death process that normally eliminates damaged or abnormal cells. By targeting BCL-2, VENCLEXTA helps restore this vital apoptosis pathway, allowing cancer cells to die naturally. This mechanism has proven effective not only in CLL but across multiple blood cancer types.
VENCLEXTA is jointly developed by AbbVie and Roche, with commercialization handled by AbbVie and Genentech (a Roche subsidiary) in the United States and by AbbVie internationally. The drug has already achieved regulatory approval in more than 80 countries worldwide.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
The Broader Significance
This approval reflects AbbVie’s commitment to advancing cancer treatment through targeted, innovative therapies. The company’s oncology pipeline includes more than 35 investigational medicines spanning blood cancers and solid tumors, with a focus on drugs that either prevent cancer cell reproduction or enable their elimination through mechanisms including small molecule therapeutics, antibody-drug conjugates, immuno-oncology treatments, multispecific antibodies, and CAR-T platforms.
The VENCLEXTA and acalabrutinib combination approval demonstrates how clinical trial data, when robust and compelling, can reshape treatment standards and expand options for patients facing serious illness.
Last Modified:
